DATE24 Jul

NIFTY 23,767 ▼ 0.43%BANK NIFTY 56,694 ▲ 0.18%NIFTY IT 28,768 ▲ 0.82%NIFTY PHARMA 25,548 ▼ 0.41%GODIGIT 256 ▼ 8.78%MOTILALOFS 872 ▼ 7.26%SYRMA 1,288 ▼ 6.64%ACE 1,039 ▲ 6.17%KPITTECH 583 ▲ 5.86%ACUTAAS 3,260 ▼ 5.77%PVRINOX 1,064 ▲ 5.61%CEMPRO 1,441 ▼ 5.00%HFCL 197 ▼ 4.91%RRKABEL 2,494 ▲ 4.85%NIFTY 23,767 ▼ 0.43%BANK NIFTY 56,694 ▲ 0.18%NIFTY IT 28,768 ▲ 0.82%NIFTY PHARMA 25,548 ▼ 0.41%GODIGIT 256 ▼ 8.78%MOTILALOFS 872 ▼ 7.26%SYRMA 1,288 ▼ 6.64%ACE 1,039 ▲ 6.17%KPITTECH 583 ▲ 5.86%ACUTAAS 3,260 ▼ 5.77%PVRINOX 1,064 ▲ 5.61%CEMPRO 1,441 ▼ 5.00%HFCL 197 ▼ 4.91%RRKABEL 2,494 ▲ 4.85%

Morning brief · Saturday, 25 July 2026

Laurus Labs’ contract manufacturing surge fuels 124% profit jump

Market pulse

Indian markets ended the week on a mixed note as the benchmark Nifty slipped below 23,800, weighed down by losses in pharmaceutical stocks. However, the banking and IT sectors bucked the trend to close in the green, while individual names like ACE and KPIT Technologies saw significant gains of over five percent.

From the investor's mind

One post worth your time, explained

@ShashankUdupa1 · on X

Laurus Labs has reported impressive financial results, with revenue growing by 29% and profit after tax (PAT) increasing by 124%. A significant driver of this growth is the Contract Development and Manufacturing Organization (CDMO) segment, whose revenue share has risen to 44% of the total, a substantial increase from single digits a few years ago. Shashank Udupa highlights that such strong earnings demonstrate a company's fundamental strength, suggesting that short-term price movements should not dictate investment decisions.

Know more about the stock

Yesterday's big moves